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Effective and tolerable salvage therapies for elderly patients with chemorefractory
acute myeloid leukemia (AML) are limited and usually do not change the poor clinical
outcome. We recently described in several chemorefractory elderly AML patients that
a novel biomodulatory treatment regimen consisting of low-dose azacitidine (AZA) in
combination with PPARγ agonist pioglitazone (PGZ) and all-trans retinoic acid (ATRA)
induced complete remission of leukemia and also triggered myeloid differentiation with
rapid increase of peripheral blood neutrophils. Herein, we further investigated our
observations and comprehensively analyzed cell differentiation in primary AML blasts
after treatment with ATRA, AZA, and PGZ ex vivo. The drug combination was found
to significantly inhibit cell growth as well as to induce cell differentiation in about
half of primary AML blasts samples independent of leukemia subtype. Notably and
in comparison to ATRA/AZA/PGZ triple-treatment, effects on cell growth and myeloid
differentiation with ATRA monotherapy was much less efficient. Morphological signs of
myeloid cell differentiation were further confirmed on a functional basis by demonstrating
increased production of reactive oxygen species as well as enhanced phagocytic activity
in AML blasts treated with ATRA/AZA/PGZ. In conclusion, we show that biomodulatory
treatment with ATRA/AZA/PGZ can induce phenotypical and functional differentiation of
primary AML blasts into neutrophil like cells, which aside from its antileukemic activity
may lower neutropenia associated infection rates in elderly AML patients in vivo. Clinical
impact of the ATRA/AZA/PGZ treatment regimen is currently further investigated in a
randomized clinical trial in chemorefractory AML patients (NCT02942758).
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INTRODUCTION
Clinical outcome of elderly AML patients refractory to intensive
chemotherapy is poor, especially when allogeneic stem cell
transplantation is not feasible due to comorbidities. Therefore,
there is an urgent clinical need for alternative treatment regimens,
which are effective and tolerable.
We recently described a small series of elderly AML patients
treated with a novel biomodulatory drug combination consisting
of low-dose AZA, the peroxisome proliferator-activated receptor
γ agonist PGZ, and ATRA (Thomas et al., 2015). Beside a
surprisingly high response rate (four of five patients achieved
complete remission), we observed in three out of five patients a
strong increase of neutrophilic granulocytes in peripheral blood
within a few days after start of therapy, which is in contrast
to standard dose azacitidine therapy, where neutropenia is a
frequent drug-related adverse event (Dombret et al., 2015). We
further analyzed neutrophilic granulocytes from peripheral blood
of ATRA/AZA/PGZ treated patients and found the same AML-
associated mutations originally described in patient’s AML blasts
at primary diagnosis, suggesting that biomodulatory therapy with
ATRA/AZA/PGZ induced differentiation in AML cells (Thomas
et al., 2015).
Induction of cell differentiation is well-described for APL
treated with ATRA alone or in combination with ATO (Lo-
Coco et al., 2013). However, beneficial effects of ATRA in non-
APL subtypes were moderate when combined with intensive
induction chemotherapy and limited to patients with ELN
favorable-risk (Schlenk et al., 2016). Although clinical phase I/II
trials evaluating ATRA in combination with hypomethylating
agents (e.g., azacitidine, decitabine) and the histone deacetylase
inhibitor valproic acid showed encouraging safety and response
data in elderly patients with high-risk MDS and AML, there
was no evidence for the restoration of ATRA-induced cell
differentiation during therapy (Soriano et al., 2007; Lübbert and
Kuendgen, 2015). To further increase the effect of ATRA and
AZA combination we included PGZ, as PGZ was described
as potential modulator in myeloid malignancies by acting on
transcription factors involved in apoptosis and cell differentiation
(Konopleva et al., 2004; Saiki et al., 2006).
Neutropenia associated bacterial and fungal infections are
major complications in AML patients and have a significant
impact on the clinical course (e.g., more hospital admissions)
as well as on the outcome of patients (Döhner et al., 2010).
Induction of myeloid differentiation leading to an early increase
Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic
leukemia; ATO, arsenic trioxide; ATRA, all-trans retinoic acid; AZA, azacytidine;
CEBPA CCAAT/enhancer-binding protein alpha; CML, chronic myeloid leukemia;
DMSO, dimethyl sulfoxide; EVI-1, ecotropic viral integration site 1; FAB, French-
American-British Cooperative Group; FCS, fetal calf serum; FLT3-ITD, FMS-
like tyrosine kinase-3 internal tandem duplication; G-CSF, granulocyte-colony
stimulating factor; GFP, green fluorescent protein; HS, human serum; MFI, median
fluorescence intensity; MDS, myelodysplastic syndrome; MIDO, midostaurin;
NBT, nitro blue tetrazolium; NOS, not otherwise specified; NPM1, nucleophosmin
1; PPARγ, peroxisome proliferator-activated receptor gamma; PGZ, pioglitazone;
PMA, phorbol-12-myristat-13-acetat; PTEN, phosphatase and tensin homolog;
ROS, reactive oxygen species; SCF, stem cell factor; WHO, World Health
Organization.
of neutrophils already during therapy might therefore decrease
the risk for serious infectious complications. However, so far
it is unclear whether neutrophils differentiated from primary
AML blasts are able to combat pathogens. We herein describe
for the first time that biomodulatory treatment of primary AML
blasts with ATRA/AZA/PGZ not merely induces morphological
changes in primary AML blasts but also promotes their
differentiation into granulocytes capable of phagocytosis and
reactive oxygen species (ROS) production.
MATERIALS AND METHODS
Culture of Leukemia Cells
AML cell line HL-60 was provided by Dr. M. Rehli, University
Hospital Regensburg. MV4-11 and MOLM-13 cell lines were
kindly provided by Dr. M. Hudecek, University Hospital
Würzburg. All cell lines were routinely tested for mycoplasma
contamination. Primary AML blasts were isolated from
peripheral blood of patients who showed more than 70%
leukemia blasts within total white blood cells at primary
diagnosis. Blood samples were drawn before start of leukemia
therapy after written informed consent in accordance with
the Declaration of Helsinki and upon approval of the study
by the ethics committee of the University Regensburg. HL-60
cells were cultured in RPMI 1640 medium (Thermo Fisher
Scientific, Waltham, MA, United States) supplemented with 10%
FCS (PAA Laboratories, Pasching, Germany), 2% Penicillin-
Streptomycin (Life Technologies), and 10 mM HEPES buffer
(Life Technologies).
Primary AML blasts were thawed and cultured in AIM-V
medium (Life Technologies) supplemented with 10% HS,
50 ng/mL stem-cell factor (SCF; PeproTech, Rocky Hill, NJ,
United States) and 50 ng/mL granulocyte-colony stimulating
factor (G-CSF; Hospira, Lake Forest, IL, United States) at a
density of 5 × 105 cells/mL in 24 well-plates. Half of medium
supplemented with cytokines was replaced on days 4, 7, and
11. ATRA, AZA, and PGZ were dissolved in DMSO. Where
indicated, single agent DMSO (0.1–0.3% Carl Roth, Karlsruhe,
Germany; equivalent amount compared to treatment samples),
ATRA (1 µM; Sigma-Aldrich, St. Louis, MO, United States),
AZA (0.1 µM; Sigma-Aldrich), PGZ (5 µM; Sigma-Aldrich), or
midostaurin (20 nM; Sigma-Aldrich) or drug combinations were
added on day 0 of culture. Due to its short half-life AZA was
added daily until day 7. Medium control contained 10% HS, SCF,
and G-CSF. AML blasts were analyzed on day 14 of culture.
Flow Cytometry and Antibodies
Flow cytometry was performed on FACSCalibur (BD Biosciences,
Franklin Lakes, NJ, United States) and analyzed using FlowJo
V10 software (Tree Star, Ashland, OR, United States). Relative
fluorescence intensities were calculated from the MFI value of the
relevant staining divided by the MFI value of the medium control
sample. Fluorochrome-labeled monoclonal antibodies were anti-
human CD11b (ICRF44), CD15 (HI98), CD33 (WM53), CD34
(581), CD80 (L307.4), CD83 (HB15e), CD86 (2331), CD117
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(YB5.B8), CD274 (MIH1), HLA-class I (G46-2.6), HLA-DR
(G46-6), and Annexin V (all BD Biosciences).
Apoptosis Measurement
The fraction of U937 cells presenting apoptotic nuclei, among
the total cell population was calculated by counting at least 300
cells in at least three different randomly selected fluorescence
microscopic fields, after staining cells with the cell-permeable
DNA-specific dye Hoechst 33342 directly added to the culture
medium at the final concentration of 10 µg/mL (Ghibelli et al.,
1995; Dini et al., 1996). Apoptosis of treated HL-60 or primary
AML blasts was determined by Annexin V staining according to
manufacturer’s instructions.
Morphological Assessment of AML Cells
For morphological analysis of myeloid cell differentiation,
cytospins were prepared by centrifugation (1.200 rpm, 10 min)
of 5 × 104 primary AML cells on microscope slides (Paul
Marienfeld GmbH, Lauda-Königshofen, Germany) using a
Shandon Cytospin 3 Cytocentrifuge (Thermo Fisher Scientific,
Waltham, MA, United States) and air drying for 5 min.
Subsequently, cytospin slides were stained for 3 min with May-
Grünwald (Merck, Darmstadt, Germany) and afterward for
13 min with 25% Giemsa solution (Merck). For each condition,
200 cells were analyzed for cellular morphology and counted
by two individuals independently using a Leica DMLB light
microscope type 020-519.511 (Leica, Wetzlar, Germany) and
Color Video Camera model MC-3289 (Horn Imaging GmbH,
Aalen, Germany).
ROS Production of Treated AML Blasts
For NBT assay (Wald et al., 2008), AML cells were seeded in 24
well-plates on day 14 of culture at a density of 1 × 106 in 0.5 mL
AIM-V medium supplemented with 10% HS and incubated
with 1 mg/mL NBT (Sigma-Aldrich) and 200 ng/mL PMA
(Sigma-Aldrich) at 37◦C for 90 min. Cells were then harvested
and cytospins were prepared as described above. Numbers of
formazan colored cells were counted for each condition in a
blinded fashion by two individuals independently.
Transformation of E. coli JM109 and
Preparation of Bacterial Suspension
JM109 E. coli bacteria were incubated with 0.25 µg enhanced
GFP plasmid DNA (Schaft et al., 2006) for 30 min on ice.
Following a heat shock for 45 s at 42◦C, JM109 were incubated
at 280 rpm, 37◦C for 40 min in standard lysogeny broth (LB)
medium. Finally, bacteria were plated on ampicillin agar plates
and incubated over night at 37◦C. Bacterial suspension was
prepared with some modifications as described before (Palazzolo
et al., 2005; Gille et al., 2006). Single bacterial clones were
picked and incubated for 10 h at 280 rpm, 37◦C in 25 mL
LB medium supplemented with ampicillin (100 µg/mL; Sigma).
Afterward, 500 µl of the bacterial suspension was transferred
to 49.5 ml LB medium supplemented with ampicillin and again
incubated at 280 rpm, 37◦C until an optical density of 0.65–
0.85 (λ = 600 nm). For opsonization, bacteria were pelletized
(1500 rpm, 10 min) and incubated in 77% Hank’s Balanced Salt
Solution supplemented with 13% PBS, 10% HS, 1 mM CaCl2,
0.5 mM MgCl2 at 280 rpm, 37◦C for 30 min.
Phagocytosis of Treated AML Blasts
Phagocytosis of GFP+ E. coli was analyzed on day 14 of AML cell
culture by incubation of 2.5 × 105 AML blasts with 6.25 × 106
GFP-transformed E. coli JM109 bacteria for 10 min at 37◦C in
77% Hank’s Balanced Salt Solution supplemented with 13% PBS,
10% HS, 1 mM CaCl2, 0.5 mM MgCl2. After cell harvest, cells
were washed four-times with PBS and analyzed for GFP+ cells by
flow cytometry.
Statistical Analysis
GraphPad Prism 7.03 (GraphPad Software, San Diego, CA,
United States) was used for statistical analysis. Friedman and
Dunn’s multiple comparisons test was used for significance
testing (non-parametric, paired analyzes). Differences were
considered statistically significant for p-values of < 0.05.
RESULTS
Anti-proliferative Effect of ATRA Is
Differently Modulated by Co-treatment
With PGZ and AZA in Myeloid Cell Lines
We first evaluated the effects of ATRA, AZA, and PGZ as single or
combined treatment on HL-60 leukemia cells (FAB M2 subtype)
in vitro. To avoid cytotoxic effects by AZA, we used a very low
dose of AZA (0.1 µM) which was at least 10-fold lower than
described in other studies (Stresemann et al., 2008; Hollenbach
et al., 2010). We observed that mono-treatment with ATRA,
double-treatment with ATRA and pioglitazone (ATRA/PGZ)
or azacitidine (ATRA/AZA) as well as the triple combination
of ATRA/AZA/PGZ strongly inhibited cell growth of HL-60
leukemia cells (Figure 1A) on day 7 of culture. In contrast, cell
growth of HL-60 cells treated with single agent AZA or PGZ, or
their combination (AZA/PGZ) was less affected when compared
to DMSO treated controls (Figure 1A). Further, we analyzed
the capacity of mono- and combined ATRA, AZA, and PGZ
treatment to induce cell differentiation in HL-60 cells by flow
cytometric analysis of CD11b surface expression, a commonly
used marker for AML differentiation (Gupta et al., 2012). Again,
on day 5 of culture only treatment with ATRA alone or in
combination with PGZ (ATRA/PGZ), AZA (ATRA/AZA), or
AZA/PGZ (ATRA/AZA/PGZ) induced a significant upregulation
of CD11b expression in HL-60 cells when compared to DMSO
treated cells (Figure 1B). In clear contrast, incubation of HL-60
cells with single agent PGZ or AZA, or AZA/PGZ combination
had no impact on CD11b expression, respectively (Figure 1B).
We then tested single agent and combined ATRA, AZA,
and PGZ treatment on pro-monocytic U937 cells. While ATRA
remains the more effective agent, AZA and PGZ display also
a certain level of activity, and mostly, they both enhanced
ATRA action, as shown by results from analysis of cell growth
(Figure 1C) and apoptosis (Figure 1D). In conclusion, the two
Frontiers in Pharmacology | www.frontiersin.org 3 November 2018 | Volume 9 | Article 1380
fphar-09-01380 November 27, 2018 Time: 13:20 # 4
Klobuch et al. Biomodulatory AML Treatment
FIGURE 1 | Treatment of HL-60 and U937 cells. (A) HL-60 cells (1.2 × 106) were incubated in RPMI supplemented with 10% FCS and as indicated with DMSO
(open circles), 1 µM ATRA (closed circle), 5 µM PGZ (open square), 0.1 µM AZA (closed square), ATRA/PGZ (open diamond), ATRA/AZA (closed diamond),
PGZ/AZA (open triangle), or ATRA/AZA/PGZ (closed triangle). On days 3, 5, and 7 during treatment, cells were counted by trypan blue staining. Data represent
means of cell numbers from three independent experiments. Error bars indicate the standard deviation. (B) HL-60 cells were treated as described in (A). On day 5 of
treatment, cells were characterized for surface-expression of the differentiation marker CD11b by flow cytometry. Shown are relative MFI values calculated by division
of the MFI of antigen staining by the MFI of DMSO staining. Data represent means and standard deviations of three independent experiments. p-Values are shown
for samples with significant differences in comparison to DMSO controls. Statistical analysis for group differences were performed using Friedman and Dunn’s
multiple comparisons test. (C,D) U937 cells were incubated in RPMI supplemented with 10% FCS and as indicated with DMSO (open circles), 1 µM ATRA (closed
circle), 5 µM PGZ (open square), 0.1 µM AZA (closed square), ATRA/PGZ (open diamond), ATRA/AZA (closed diamond), PGZ/AZA (open triangle), or
ATRA/AZA/PGZ (closed triangle). From day 0 to day 4 during treatment, cells were analyzed for cell growth (C) and apoptosis (D). Data represent means from two
independent experiments. Error bars indicate the standard deviation.
myeloid cell lines show similar sensitivity to ATRA, but different
susceptibility to the combination treatments. Nonetheless, ATRA
seems to be the key component for induction of cell death or
differentiation in the analyzed cell lines.
ATRA/AZA/PGZ Triple-Therapy Induces
Apoptosis and Inhibits Cell Growth of
Primary AML Blasts
Since ATRA mono-treatment already induced differentiation of
HL-60 cells as has also been reported by others (Gupta et al.,
2012), we next analyzed the effects of ATRA/AZA/PGZ treatment
on primary non-APL AML blasts isolated from 14 patients
with different AML FAB and WHO subtypes (Table 1). Here,
triple-treatment with ATRA/AZA/PGZ significantly inhibited
growth of primary AML blasts (median of relative cell
number normalized to medium 30.8%) in comparison to
ATRA mono-treatment (median 80.1%; p = 0.04) or DMSO
control (median 97.9%; p = 0.004) during 14 days of culture
(Figure 2A). Due to limited patient material and the most
striking effects of ATRA with HL-60 and U937 cells, we restricted
controls to ATRA mono-treatment, DMSO, and medium
control. In line with decreased proliferation, ATRA/AZA/PGZ
treatment also induced an increase in apoptosis rate (median
of annexin-V positive cells 143.5%), which was less distinct
with ATRA (median 126.5%; p = 0.07) and significantly lower
in DMSO controls (median 97.5%; p = 0.002) (Figure 2B).
Most notably, effects on proliferation and apoptosis with
ATRA/AZA/PGZ triple-treatment were markedly stronger than
those with ATRA mono-therapy (Figures 2A,B). Of note, not
all individual AML samples were sensitive to growth inhibition
and apoptosis with ATRA/AZA/PGZ treatment (e.g., AML144),
whereas other samples remained unaffected (e.g., AML111)
(Figures 2C,D).
ATRA/AZA/PGZ Induces Differentiation
in Primary AML Cells
We further evaluated whether ATRA/AZA/PGZ therapy
promotes cell differentiation in primary AML blasts.
Morphological assessment of individual AML samples on
day 14 of culture demonstrated signs of differentiation as can
be seen from increased and brightened cytoplasm, granular
formation and altered nuclear morphology in AML cells during
ATRA/AZA/PGZ therapy (e.g., AML101; Figure 3A picture I),
which was less distinct with ATRA mono-treatment and absent
in DMSO or medium controls (Figure 3A, pictures II–IV). In
contrast, normal granulocytes or monocytes were not detected in
the samples.
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TABLE 1 | Patients characteristics, FAB-classification, molecular and cytogenetics of primary AML samples.
Sample FAB WHO Age % Blasts in PB Molecular genetics Cytogenetics
AML007 M2 AM L with maturation 55–60 92 FLT3-ITD 46, XY
AML011 M5 Acute monoblastic and monocytic leukemia 85–90 95 nd nd
AML012 M4 AML with mutated NPM1 55–60 86 FLT3-ITD NPM1 mut 46, XY
AML014 nd AML, NOS 70–75 95 nd nd
AML101 M4 Acute myelomonocytic leukemia 30–35 90 FLT3-ITD 46, XY
AML109 nd AML with myelodysplasia-related changes 80–85 86 nd 46, XXder(7), t(7;11), dupl(11)
AML110 M5 AML with mutated NPM1 70–75 90 NPM1 mut 46, XY
AML111 M2 AML with biallelic mutation of CEBPA 45–50 96 Biallelic CEBPA mut 46, XY
AML128 M4 Acute myelomonocytic leukemia 75–80 93 nd nd
AML135 M2 AML with mutated NPM1 45–50 70 FLT3-ITD NPM1 mut nd
AML144 nd AML with mutated NPM1 85–90 80 FLT3-ITD NPM1 mut nd
AML147 nd AML, NOS 70–75 86 FLT3-ITD 46Xdel(X), del(18)
AML151 MO AML with mutated NPM1 65–70 90 FLT3-ITD NPM1 mut 46, XX
AML172 M1 AML without maturation 65–70 70 FLT3-ITD 46, XY
CEBPA, CCAAT/enhancer-binding protein alpha; FAB, French-American-British Cooperative Group; NOS, not otherwise specified; NPM1, nucleophosmin 1; FLT3, FMS-
like tyrosine kinase-3; -ITD: internal tandem duplication; nd, not determined; WHO, World Health Organization.
FIGURE 2 | Cell growth and apoptosis of primary AML blasts. (A,B) Primary AML blasts (5 × 105) were incubated in AIM-V medium supplemented with 10% HS,
G-CSF and SCF (each 50 ng/mL) and as indicated with medium, DMSO, ATRA, or ATRA/AZA/PGZ. On 14 of treatment, cell numbers were measured by
conventional trypan blue staining. (A) Shows cell numbers normalized to medium (n = 14 per group), (B) shows Annexin positive cells normalized to medium
(medium = 100%; n = 14 per group). Symbols represent individual patient samples and horizontal bars mark median values. Statistical analysis for group differences
were performed using Friedman and Dunn’s multiple comparisons test. (C) Primary AML blasts (5 × 105) of patient sample AML144 (left panel) or AML111 (right
panel) were incubated as described in (A). On days 7 and 14 of treatment, cell numbers were measured by conventional trypan blue staining. (D) AML blasts as
described in (A) were characterized by Annexin V binding 14 days after treatment. Shown are % Annexin positive cells of AML111 (white bars) and AML144 (black
bars).
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Whereas ATRA/AZA/PGZ triple-therapy induced
morphological signs of cell differentiation in 6 of 12 analyzed
AML samples, some AML samples (AML011, AML012, AML110,
AML128, and AML151) remained unaffected (Figure 3B).
Overall, ATRA/AZA/PGZ treatment (median normalized to
medium 204.3%) induced significantly stronger differentiation
in primary AML blasts than DMSO controls (median 102.6%;
p = 0.005). Again and although not significant, effects with ATRA
mono-treatment were less potent than those observed with
ATRA/AZA/PGZ (median 143.5%; p = 0.057) (Figure 3B).
To further dissect the role of each drug, we tested single
(ATRA, AZA, PGZ), double (ATRA/AZA, ATRA/PGZ,
PGZ/AZA), and triple combination (ATRA/AZA/PGZ) with
sample AML101 (Figure 3C). As observed in AML cell lines
(Figure 1) ATRA mono-treatment had significant differentiation
effects. However, also AZA mono-treatment induced significant
morphological changes compared to controls (Figure 3C).
Whereas ATRA/AZA combination showed an additive
effect, ATRA/PGZ combination was not superior compared
to ATRA mono-treatment. Again, the triple combination
ATRA/AZA/PGZ induced the most pronounced differentiation
effects in primary AML101 blasts.
In addition to morphological changes we investigated
immunophenotypical changes of differentiation markers
FIGURE 3 | Morphological differentiation of primary AML blasts. (A) Primary AML blasts (5 × 105) were treated as described in Figure 2. On day 14 after start of
treatment, cells (5 × 104) were analyzed by light microscopy after centrifugation on microscope slides and May-Grünwald and Giemsa staining. Shown are AML cells
of sample AML101 after treatment with ATRA/AZA/PGZ (I), ATRA (II), DMSO (III), or medium (IV), respectively. (B) Summary of 12 primary AML patient’s samples on
day 14 of treatment as described in (A). Cells with morphological signs of differentiation were normalized to medium controls. Symbols represent individual patient
samples and horizontal bars mark median values. (C) On day 14 of treatment with ATRA, PGZ, AZA, ATRA/AZA, ATRA/PGZ, PGZ/AZA, ATRA/AZA/PGZ, or DMSO
sample AML101 was analyzed for morphological changes as described in (A). Cells with morphological signs of differentiation were normalized to medium controls.
Data represent means of morphological changes from two independent experiments. Error bars indicate the standard deviation. (D) Primary AML samples (n = 14) at
day 14 of treatment. Shown are the relative MFIs of CD11b staining normalized to medium. Symbols represent individual patient samples and horizontal bars mark
median values. Statistical analysis for group differences were performed using Friedman and Dunn’s multiple comparisons test.
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(CD11b, CD15, CD33, CD34, CD80, CD83, CD86, CD117,
CD274, HLA-ABC, and HLA-DR). Figure 3D shows exemplified
changes of CD11b expression of treated AML blasts. However,
no marker showed a significant upregulation upon treatment
with ATRA/AZA/PGZ compared to controls (data not
shown).
ATRA/AZA/PGZ Treatment Enhances
ROS Production and Phagocytosis
Activity in Primary AML Cells
To investigate, if ATRA/AZA/PGZ treatment promotes
functional differentiation in primary AML blasts, we evaluated
their ability for ROS production and phagocytosis. After
phagocytosis, neutrophils eliminate pathogens (e.g., bacteria)
through the generation of ROS (Hong, 2017), which induces
microbial DNA damage. Intracellular ROS production in
stimulated cells can be measured by reduction of NBT
into formazan to form an insoluble blue-black precipitate,
which can be detected as intracellular color-change (Wald
et al., 2008). NBT also serves as a very sensitive marker
for myeloid differentiation (Gupta et al., 2012). Figure 4A
shows an example of NBT staining in AML blasts after
PMA stimulation. Herein, AML101 cells stained strongly
positive for ROS on day 14 of ATRA/AZA/PGZ treatment
(Figure 4A, picture I) which was clearly less pronounced
in control treatments with ATRA, DMSO, or medium
(Figure 4A, pictures II–IV). In line with morphological
signs of differentiation (Figure 3), quantity of NBT staining
differed between AML blasts of individual patients and was
significantly higher in samples treated with ATRA/AZA/PGZ
(median 207.0%) when compared to DMSO control (median
103.0%; p = 0.0009) (Figure 4B). Although not statistically
significant, ATRA mono-treated AML samples trended to lower
numbers of ROS producing cells (Figure 4B). Most notably,
AML samples with higher ROS production in NBT staining
(AML101, AML135, AML144, AML147) were identical with
samples that showed strongest signs of morphological and
immunophenotypical differentiation during ATRA/AZA/PGZ
triple-therapy (Figure 3).
In addition to ROS production (Figure 4B), ATRA/AZA/PGZ
combination was indeed able to induce functional differentiation
in primary AML cells as shown by a significant increase of
phagocytosis of GFP labeled E. coli in ATRA/AZA/PGZ treated
samples (median 112.0%) (Figure 4C). In contrast, phagocytosis
in DMSO treated samples were significantly lower (median
91.0%; p = 0.003) and comparable to ATRA treated cells (median
95.0%; p = 0.30) (Figure 4C). Again, phagocytosis was most
evident in AML blasts from patient 101 (AML101) (Figure 4D,
left panel).
Effects of Midostaurin Treatment in
FLT3-ITD+ AML Cell Lines
Since most AML samples responding to ATRA/AZA/PGZ
treatment were positive for FMS-like tyrosine kinase-3 internal
tandem duplication (FLT3-ITD), we analyzed the effects of
the multikinase inhibitor midostaurin (MIDO) as single agent
as well as in combination with ATRA, AZA, and PGZ on
FLT3-ITD+ AML cell lines MV4-11 (Figure 5A) and MOLM-
13 (Figure 5B). In line with HL-60 cells (Figure 1A), ATRA
mono-treatment significantly inhibited cell growth compared
to DMSO, whereas single agent AZA or PGZ had almost
no effect on cell proliferation. Growth inhibitory effects of
MIDO mono-treatment were comparable to those of ATRA,
whereas combination therapy with ATRA/MIDO showed an
additive effect on cell number leading to an almost complete
cell death. Because of the strong effects of ATRA/MIDO
combination leading to an almost complete cell death on
day 3 of treatment, analyses of additional effects (e.g.,
CD11b expression, differentiation, phagocytosis) during triple or
ATRA/PGZ/AZA/MIDO treatment were not valid. However, on
days 1 and 2 of treatment, AZA, PGZ, or AZA/PGZ did not
induce additional effects to ATRA/MIDO combination (data not
shown).
DISCUSSION
We herein describe for the first time that a biomodulatory
treatment regimen consisting of ATRA, low-dose AZA, and
PGZ induces myeloid differentiation in primary AML blasts
in vitro. Differentiated granulocyte like cells were characterized
by morphological cell differentiation, expression of the myeloid
differentiation markers, ROS production and most notably
phagocytic activity. In addition, these observations parallel
our previous data in patients with refractory AML, in which
ATRA/AZA/PGZ treatment induced considerable increases of
peripheral leukocyte counts while neutrophils still expressed
molecular aberrations of the blast population (Thomas et al.,
2015).
Most in vitro studies have investigated differentiation-
inducing drugs such as ATRA and AZA in AML cell lines
(Fujiki et al., 2012). As shown with the ATRA effect on
HL-60 cells (Figure 1), however, results on cell lines may
not necessarily correlate with data obtained from primary
AML blasts of patient samples (Figures 2–4). Here, in
comparison to ATRA mono-treatment, the combination of
ATRA/AZA/PGZ was more potent to induce cell differentiation
and was directly associated with increased ROS production
and phagocytosis. Nevertheless, near half of 14 AML samples
analyzed did not respond to ATRA/AZA/PGZ treatment and
neither showed cytomorphological changes nor elevated ROS
levels. However, although samples AML110 and AML128 showed
a clear upregulation of CD11b (Figure 3C), we didn’t observe
morphological changes or increased ROS production in those
AML samples. In contrast, in other samples (e.g., AML172) we
observed a downregulation of CD11b during ATRA/AZA/PGZ
treatment, which might be explained by the heterogeneity
of individual AML samples. This effect also indicates that
CD11b upregulation did not clearly correlate with functional
granulocytic differentiation in some leukemia blasts.
Differentiation of myeloid progenitors into neutrophils
has been successfully achieved in patients with APL by
ATRA treatment (Lo-Coco et al., 2013; Cicconi et al., 2016).
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FIGURE 4 | Reactive oxygen species production and phagocytosis of AML blasts. (A) Primary AML blasts were treated as described in Figure 2. On day 14 of
treatment, 5 × 105 AML blasts were incubated with NBT (1 mg/mL) and PMA (200 ng/mL) for 90 min. Subsequently, cells were centrifuged on microscope slides for
light microscopy. Shown are AML blasts of sample AML101 after treatment with ATRA/AZA/PGZ (I), ATRA (II), DMSO (III), or medium (IV), respectively. (B) Summary
of primary AML samples (n = 11) on day 14 days of treatment as described in (A). NBT positive cells were counted in a blinded fashion and were normalized to
medium. Symbols represent individual patient samples and horizontal bars mark median values. Statistical analysis for group differences were performed using
Friedman and Dunn’s multiple comparisons test. (C,D) Primary AML blasts were treated as described in Figure 2. On day 14 of treatment, 2.5 × 105 AML blasts
(n = 11 patients) were incubated with 6.25 × 106 GFP-labeled E. coli bacteria for 10 min. Subsequently, cells were analyzed by flow cytometry for GFP positive cells.
(C) Summary of data (n = 11 AML samples) representing MFIs of GFP signal normalized to medium controls. Symbols represent individual patient samples and
horizontal bars mark median values. Statistical analysis for group differences were performed using Friedman and Dunn’s multiple comparisons test. (D) Individual
overlay plots and MFI of GFP signals measured with AML101 and AML147.
In APL, treatment with ATRA and chemotherapy or more
recently in combination with ATO, is highly effective and
is characterized by differentiation of promyelocytes into
neutrophils. Moreover, clinical data on the biomodulatory
treatment regimen ATRA/ATO, meanwhile approved in low-
risk APL, indicate that frequently occurring FLT3 mutations
in APL are no longer of prognostic significance (Cicconi
et al., 2016). Interestingly, all AML samples responding to the
ATRA/AZA/PGZ combination in our study were positive for
FLT3-ITD, suggesting that also AML with high-risk features may
benefit from our novel ATRA/AZA/PGZ treatment approach.
Since MIDO was recently approved for the treatment of FLT3
mutated AML patients, we aimed to analyze the additional effects
of MIDO in combination with ATRA/PGZ/AZA treatment. As
already described (Ma et al., 2016), combination of ATRA and
MIDO showed additive effects (Figure 5), which could in our
system not be increased by the addition of AZA and/or PGZ.
However, because of the small sample number, we cannot draw
any conclusions to use FLT3-ITD as a biomarker for treatment
response, which should be investigated with larger sample
numbers as well as in clinical trials.
Several in vitro studies investigated the effects of ATRA
in combination with different other drugs in non-APL AML:
for example, ATRA together with AZA has been shown to
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FIGURE 5 | Biomodulatory treatment of AML cell lines in combination with midostaurin. (A) MV4-11 and (B) MOLM-13 cells were incubated in RPMI supplemented
with 10% FCS and treated with single agent DMSO, ATRA, AZA, PGZ, MIDO or combinations thereof. On day 3 during treatment cells were counted by trypan blue
staining. Data represent means of cell numbers from three independent experiments. Error bars indicate the standard deviation. Statistical analysis for group
differences compared to DMSO were performed using Friedman and Dunn’s multiple comparisons test. ns p > 0.05, ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001,
∗∗∗∗p ≤ 0.0001.
induce higher expression of CD11b in MLL-AF9-expressing
AML cell lines (Fujiki et al., 2012). Another combination
already tested in a clinical phase II trial was ATRA, AZA,
and valproic acid, which led to an overall response rate of
26% in patients with refractory/relapsed as well as previously
untreated AML and MDS patients (Raffoux et al., 2010).
However, signs of myeloid differentiation were not described
in those patients. Overall, the efficacy of ATRA in non-
APL AML is poor. While addition of ATRA to intensive
chemotherapy resulted in better overall survival in the NPM1
mutated subgroup (Schlenk et al., 2009, 2016), large studies
by others could not confirm beneficial effects of ATRA in
AML patients (Estey et al., 1999; Milligan et al., 2006; Burnett
et al., 2010), which may be due to the timing of ATRA
dosing and/or different patient populations. A more recent study
by Verhagen et al. (2016) demonstrated that ATRA induces
differentiation, decreased clonogenic capacity as well as leukemic
engraftment in a poor prognostic subgroup of EVI-1 positive
AML.
Since epigenetic reprogramming (e.g., by inhibition of the
demethylase LSD1) has been shown to unlock the ATRA-
induced therapeutic response in non-APL AML (Schenk et al.,
2012), it might well be that ATRA/AZA/PGZ treatment also
activates the ATRA-driven differentiation pathway by modifying
the epigenetic state of leukemic cells. Indeed, the ability of the
cytidine nucleoside analog AZA to induce myeloid differentiation
is attributed to its activity as hypomethylating agent, even at
doses lower than those used in AML (Ley et al., 1982; Taylor
et al., 1984; Hollenbach et al., 2010). After incorporation of
AZA into both RNA and DNA, the mechanism of action
includes depletion of DNA methyltransferases, hypomethylation
of DNA as well as induction of DNA damage (Kiziltepe
et al., 2007; Stresemann et al., 2008; Flotho et al., 2009).
While clinically achievable plasma concentrations of AZA are
between 3 and 11 µM in patients with MDS treated with the
clinically approved AZA dosage (Marcucci et al., 2005), effects
on gene regulation in in vitro studies were already detected at
concentration ≤ 1 µM (Stresemann et al., 2008; Hollenbach
et al., 2010). However, reduced cell viability and cytotoxicity in
AML cell lines have also been described at AZA concentrations
of 1 µM (Hollenbach et al., 2010), which was out of action
and could not be observed at concentrations of 0.1 µM in our
study.
PPARγ agonists (e.g., PGZ) have also been suggested as
potential modulators in myeloid leukemia by activating the
transcriptional activity of target genes that control apoptosis
and differentiation (Konopleva et al., 2004; Saiki et al., 2006) as
well as by downregulation of the STAT5-driven quiescence of
the leukemic stem cell pool (Prost et al., 2015). Furthermore,
reactivation of KLF4 expression through modulation of
PPARγ signaling, exerted a multifaceted tumor-suppressive
effect in CDX2 positive myeloid leukemia cell lines and
primary AML blasts (Faber et al., 2013), suggesting PPARγ
agonists as a therapeutic modality in a large proportion
of AML patients. As phosphatase and tensin homolog
(PTEN) is one of the primary targets of PML/RARA in
APL (Noguera et al., 2016), and loss of PTEN protein plays
a critical role in determining the disease severity in myeloid
malignancies (Liu et al., 2016), up-regulation of non-mutated
PTEN by PGZ (Patel et al., 2001) could be an additional
molecular mechanism explaining the combined activity of
ATRA/AZA/PGZ. In vivo, administration of PPARγ agonists
additionally induced BM adipogenesis, which rescued healthy
hematopoietic maturation while repressing leukemia growth
(Boyd et al., 2017). Together, these reports suggest a potential
beneficial role of PGZ to synergize with ATRA and AZA in
terms of myeloid differentiation and anti-leukemic activity in
AML.
From our experiments, we cannot draw conclusions about
the contribution of every single drug to the observed effects,
mostly because we observed much heterogeneity in the response
in various patients. Heterogeneity is confirmed by comparison
of two cell lines HL-60 and U937, which show different
response to AZA and PGZ. More studies will be thus
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required to understand the molecular determinants responsible
for these differences. Detailed analyses of sample AML101
suggests that the combination ATRA/AZA might be similarly
effective compared to the triple combination ATRA/AZA/PGZ
(Figure 3C). However, clinical data showed only modest effects
of ATRA added to hypomethylating agents (Soriano et al., 2007;
Lübbert and Kuendgen, 2015), which implicates the need for
additional substances like, e.g., PGZ.
CONCLUSION
We show herein for the first time that biomodulatory treatment of
primary AML blasts with ATRA/AZA/PGZ leads to phenotypical
and functional differentiation of leukemic cells into neutrophil
like cells in a significant fraction of patient samples in vitro.
A potential clinical benefit aside from anti-leukemic activity
might be a lower rate of AML- and therapy-related neutropenia
and lower incidences of severe infections. These promising data
with ATRA/AZA/PGZ as well as our small case series (Thomas
et al., 2015) will now be verified in an ongoing phase II trial
comparing ATRA, low-dose AZA, and PGZ with standard-dose
AZA in elderly AML patients’ refractory to intensive induction
chemotherapy (NCT02942758).
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